INVO Fertility is a four-clinic United States fertility operator whose investment debate is no longer about whether the INVOcell device can reinvent assisted reproduction. The debate is whether a still-thin clinic platform can generate enough local earnings to carry a public-company cost stack that continues to burn cash even as the clinics themselves print a profit before corporate charges. Second-quarter revenue was $2,175,485. That print sat 17% above the year-ago period, almost entirely because clinic work now dominates the mix and product sales have shrunk to a rounding error. The market values the equity at $2,340,004, a capitalization that prices scrap-value optionality rather than a finished consolidator, and that gap is the entire case.
The mechanism behind the print is two named transactions rather than a sudden boom in same-clinic demand. Family Beginnings, the Indianapolis practice closed in February 2026, delivered its first full quarter inside the consolidated numbers and is the main reason clinic revenue advanced. In June 2026 the company bought the remaining interest in the Birmingham joint venture, converting a shared clinic into a wholly owned subsidiary and booking a $2,452,032 remeasurement gain. That gain, not clinic cash, is what flipped the quarter to $888,740 of net income. Shareholders who treat the headline profit as operating proof are reading an accounting step-up as if it were a patient-volume inflection.
The tension is that clinic-level Adjusted EBITDA, the non-GAAP earnings of the fertility sites before corporate and public-company costs, reached $333,026 in the second quarter, while consolidated Adjusted EBITDA was still a $1,032,660 loss. Cash rose to $3,732,945 only because financing inflows outran an operating cash burn of $3,018,022 in the first half. Management still writes that those facts raise substantial doubt about the ability to continue as a going concern, the accounting phrase that means current resources do not cover the next year of operations and debt service without new capital. The Alumni Capital purchase agreement, already drawn for about $3,591,000 through share sales, is the live funding pipe and the live dilution machine.
What decides the equity from here is observable and narrow. Clinic-Level Adjusted EBITDA either keeps compounding toward a run-rate that can absorb the corporate overhead, or it plateaus while the equity line keeps issuing stock into a $0.9334 last sale. The next several quarterly filings settle that question more cleanly than another remeasurement gain or another reverse split. If clinic contribution stalls near the recent print while the share count keeps climbing from the 2,506,969 shares outstanding in mid-August, the market's scrap-value read is the correct one.